Cover Image
市場調查報告書

受體酪胺酸·蛋白激酶 ERBB 3:開發中產品分析

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365768
出版日期 內容資訊 英文 109 Pages
訂單完成後即時交付
價格
Back to Top
受體酪胺酸·蛋白激酶 ERBB 3:開發中產品分析 Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 109 Pages
簡介

本報告提供以受體酪胺酸·蛋白激酶 ERBB 為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊3。

簡介

  • 調查範圍

受體酪胺酸·蛋白激酶 ERBB 3 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • 第一三共
  • Etubics Corporation
  • F. Hoffmann-La Roche Ltd.
  • GamaMabs Pharma S.A.
  • GlaxoSmithKline Plc
  • Hanmi Pharmaceuticals, Co. Ltd.
  • ImmunoGen, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Merus B.V.
  • Novartis AG
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sorrento Therapeutics, Inc.
  • Symphogen A/S
  • Takis S.r.l.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0221TDB

Summary

Global Markets Direct's, 'Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
  • The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) Overview
  • Therapeutics Development
    • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Stage of Development
    • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Therapy Area
    • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Indication
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Companies
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Products under Development by Universities/Institutes
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • AVEO Pharmaceuticals, Inc.
    • Daiichi Sankyo Company, Limited
    • Etubics Corporation
    • F. Hoffmann-La Roche Ltd.
    • GamaMabs Pharma S.A.
    • GlaxoSmithKline Plc
    • Hanmi Pharmaceuticals, Co. Ltd.
    • ImmunoGen, Inc.
    • Kolltan Pharmaceuticals, Inc.
    • Merrimack Pharmaceuticals, Inc.
    • Merus B.V.
    • Novartis AG
    • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Sorrento Therapeutics, Inc.
    • Symphogen A/S
    • Takis S.r.l.
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles
    • AV-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AV-353 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BA-0702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elgemtumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETBX-031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FCN-411 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2849330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • H4B-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • huHER3-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KTN-3379 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lumretuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCLA-125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MM-141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize HER-3 for Breast and Pancrestic Cancers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patritumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pirotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • poziotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seribantumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sym-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TK-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target HER1, HER2 and HER3 for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Projects
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products
  • Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Featured News & Press Releases
    • Jun 06, 2016: Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
    • May 31, 2016: Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer
    • May 18, 2016: Merrimack to Present Data on Seribantumab at the 2016 American Society of Clinical Oncology Annual Meeting
    • May 18, 2016: Kolltan Pharmaceuticals to Report KTN3379 Clinical Data in an Oral Presentation at the Upcoming 2016 American Society of Clinical Oncology Annual Meeting
    • May 17, 2016: Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series
    • May 02, 2016: AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
    • Apr 20, 2016: Kolltan Pharmaceuticals Presents Preclinical Data on KTN3379 at the 2016 American Association for Cancer Research Annual Meeting
    • Mar 16, 2016: Merrimack to Present on MM-141 (istiratumab) at the 2016 American Association for Cancer Research Annual Meeting
    • Mar 07, 2016: Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor
    • Dec 22, 2015: Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration
    • Dec 08, 2015: Spectrum Pharmaceuticals Highlights Abstracts on Poziotinib at the San Antonio Breast Cancer Symposium
    • Nov 20, 2015: Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol to FDA as Part of an Investigational New Drug Application for Poziotinib
    • Nov 06, 2015: Kolltan Pharmaceuticals Presents KTN3379 Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Oct 30, 2015: Kolltan To Present Preclinical Data on KTN3379 at the AACR-NCI-EORTC International Conference
    • Oct 16, 2015: Kolltan Pharmaceuticals Announces Interim Efficacy Data from KTN3379 Phase 1b Clinical Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by AstraZeneca Plc, H1 2016
  • Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Pipeline by Etubics Corporation, H1 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Pipeline by GamaMabs Pharma S.A., H1 2016
  • Pipeline by GlaxoSmithKline Plc, H1 2016
  • Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Pipeline by ImmunoGen, Inc., H1 2016
  • Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
  • Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Pipeline by Merus B.V., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., H1 2016
  • Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
  • Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Pipeline by Symphogen A/S, H1 2016
  • Pipeline by Takis S.r.l., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Discontinued Products, H1 2016
  • Discontinued Products (Contd..1), H1 2016
  • Discontinued Products (Contd..2), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top